Ravagalimab represents a significant advance in immunotherapy. This biologic selectively blocks the role of this specific protein, a receptor involved in inflammation. Early clinical trials have shown encouraging data, https://ravagalimab-anti-cd40-an495421.wikicorrespondence.com/user